儿童祛痰类化学药风险干预研究  

Risk intervention of children's expectorant medicines

作　　者：马辉[1] 金丹[1] 赵频[2] 王春婷[3] 魏晶[1] 田春华[3] 杜晓曦[3] 

机构地区：[1]辽宁省药品不良反应监测中心,沈阳110003 [2]沈阳药科大学,沈阳110016 [3]国家药品不良反应监测中心,北京100045

出　　处：《中国新药杂志》2014年第4期489-492,共4页Chinese Journal of New Drugs

摘　　要：通过检索查阅国家食品药品监督管理局、美国FDA、欧盟药品评价局(EMEA)、日本厚生劳动省、世界自我药疗产业协会(WSMI)等网站,对我国儿童祛痰药的种类及国内外儿童祛痰药的管理情况进行介绍,并对儿童用药的风险来源进行分析。总结欧、美、日等国家对儿童使用祛痰类化学药品的风险控制措施,提出规范我国使用儿童祛痰类化学药的相关建议。Through searching the websites of FDA, EMEA, Japan＇s Ministry of Health, Labor and the State Food and Drug Administration （SFDA）, the US Welfare （MHLW） and WSMI, we introduced the types of children＇s expectorant medicines in our country and the management status of children＇s expectorant medicine home and abroad, and analyzed the risk source of children＇s medicine use. Moreover, we searched and summarized the risk control measures taken by Europe, the US and Japan on the use of children＇s expectorant chemical drugs Based on these, we put forward relevant suggestions on regulating the use of children＇s expectorant chemical medicines in our country

关 键 词：儿童祛痰药 风险来源 干预措施 

分 类 号：R95[医药卫生—药学]